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Background
Subunit vaccines are often poor immunogens compared
to live-attenuated and whole-inactivated virus vaccines.
One reason is the lack of costimulatory signals provided
by various components of live-attenuated and whole-
inactivated vaccines. Here we improved the immuno-
genicity of the HIV-1 envelope glycoproteins (Env) by
direct fusion to a costimulatory molecule, CD40 ligand
(CD40L), which we term 'cis-adjuvant'. The rationale was
to target the antigen directly to dendritic cells (DC) and B
cells, while at the same time activating these cells.
Methods
Chimeric Env-CD40L containing a stabilized gp140
(SOSIP.R6), a GCN4-based trimerization domain, and
the globular domain of human or mouse CD40L, was
constructed and expressed transiently expressed in 293T
cells. The expression and trimerization was analyzed by
SDS-PAGE, BN-PAGE and analytical size exclusion chro-
matograph. The interaction with ligands and neutralizing
antibodies was monitored by immunoprecipitation. The
immunomodulatory properties on monocyte-derived
immature DCs were tested. After incubation with imma-
ture monocyte-derived DC, the upregulation of DC matu-
ration markers was monitored by FACS and the secretion
of cytokines was analyzed by ELISA. Mice were immu-
nized with plasmids encoding gp140 or gp140-CD40L via
intramuscular or dermal (gene gun) routes and the Env-
specific antibody response was followed by ELISA.
Results
The trimeric gp140-CD40L construct interacted with CD4
and CD40 and was recognized by neutralizing antibodies.
Moreover, gp140-CD40L was able to activate dendritic
cells and induce secretion of cytokines from these cells.
Importantly, gp140-CD40L induced ~6-10-fold higher
gp120-specific antibody titers than gp140 alone in mice
vaccinated via intramuscular or dermal DNA immuniza-
tion routes.
Conclusion
Fusion to CD40L enhanced the immunogenicity of HIV-1
Env trimers. Antigen targeting via CD40L or other 'cis-
adjuvants' may have wider applicability in subunit vac-
cine development.
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